Publications

BibTex format

@article{Nagler:2023:10.1186/s13045-023-01450-4,
author = {Nagler, A and Labopin, M and Blaise, D and Raiola, AM and Corral, LL and Bramanti, S and Sica, S and Kwon, M and Koc, Y and Pavlu, J and Kulagin, A and Busca, A and Rodriguez, AB and Remenyi, P and Schmid, C and Brissot, E and Sanz, J and Bazarbachi, A and Giebel, S and Ciceri, F and Mohty, M},
doi = {10.1186/s13045-023-01450-4},
journal = {Journal of Hematology and Oncology},
title = {Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT},
url = {http://dx.doi.org/10.1186/s13045-023-01450-4},
volume = {16},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8 years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) ≥ 3 21.3% versus 40.8%, p < 0.0001 and Karnofsky performance status (KPS) with KPS ≥ 90 in 78% versus 68.5%, respectively, p = 0.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9 months, respectively, p = 0.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, p < 0.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR) = 0.98, p = 0.9 and 23.4% versus 20.6%, HR = 0.92, p = 0.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR = 0.95, p = 0.67; 61.4% versus 66.4%, HR = 0.91, p = 0.51 and 46.3% versus 48.2%, HR = 0.92, p = 0.48, respectively. Similarly, the incidence
AU  - Nagler,A
AU  - Labopin,M
AU  - Blaise,D
AU  - Raiola,AM
AU  - Corral,LL
AU  - Bramanti,S
AU  - Sica,S
AU  - Kwon,M
AU  - Koc,Y
AU  - Pavlu,J
AU  - Kulagin,A
AU  - Busca,A
AU  - Rodriguez,AB
AU  - Remenyi,P
AU  - Schmid,C
AU  - Brissot,E
AU  - Sanz,J
AU  - Bazarbachi,A
AU  - Giebel,S
AU  - Ciceri,F
AU  - Mohty,M
DO  - 10.1186/s13045-023-01450-4
PY  - 2023///
SN  - 1756-8722
TI  - Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
T2  - Journal of Hematology and Oncology
UR  - http://dx.doi.org/10.1186/s13045-023-01450-4
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000996785900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01450-4
UR  - http://hdl.handle.net/10044/1/107835
VL  - 16
ER  -

Download

Jiri Pavlu

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)